Happy Family Pharmacy is pleased to offer Acular, a trusted and effective ophthalmic solution for the management of ocular pain, inflammation, and itching. Eye discomfort, whether resulting from surgical procedures, seasonal allergies, or other inflammatory conditions, can impact quality of life, interfering with vision, concentration, and daily activities. At Happy Family Pharmacy, we make Acular available over the counter, providing patients with convenient and affordable access to the relief they need.
Understanding acular and its active ingredient
Acular is the brand name for ketorolac tromethamine, a potent nonsteroidal anti inflammatory drug formulated as a sterile ophthalmic solution for topical application to the eye. Ketorolac belongs to the same class of medications as ibuprofen, naproxen, diclofenac, and other NSAIDs that are widely used to treat pain and inflammation throughout the body. The ophthalmic formulation of ketorolac delivers the medication directly to the affected ocular tissues, providing targeted relief with minimal systemic absorption.
The anti inflammatory and analgesic properties of ketorolac are attributable to its ability to inhibit the cyclooxygenase enzymes, COX-1 and COX-2, which are responsible for the conversion of arachidonic acid into prostaglandins. Prostaglandins are lipid mediators that play a central role in the inflammatory response, promoting vasodilation, increasing vascular permeability, sensitizing pain nerve endings, and contributing to the redness, swelling, pain, and heat that characterize inflammation. By blocking prostaglandin synthesis, ketorolac reduces these manifestations of inflammation.
In the eye, prostaglandins are involved not only in ocular inflammation and in the regulation of intraocular pressure, the mediation of the miotic response to surgical trauma, and the pathogenesis of cystoid macular edema following cataract surgery. The ability of ketorolac to suppress prostaglandin mediated ocular inflammation makes it a valuable therapeutic agent in various clinical settings, from routine postoperative care to the management of chronic allergic eye conditions.
Clinical indications and therapeutic applications
Acular is indicated for the treatment of ocular pain, burning, and stinging following corneal refractive surgery. This includes procedures such as photorefractive keratectomy, radial keratotomy, and other surgical interventions on the cornea that are associated with significant postoperative discomfort. The pain following these procedures can be severe, and effective analgesia is essential for patient comfort and for facilitating the healing process.
Also, Acular is indicated for the treatment of ocular itching associated with seasonal allergic conjunctivitis. Allergic conjunctivitis is an extremely common condition affecting millions of people worldwide, characterized by itching, redness, tearing, and swelling of the conjunctiva in response to environmental allergens such as pollen, mold spores, animal dander, and dust mites. By suppressing the inflammatory cascade that underlies the allergic response, Acular provides rapid and effective relief from the maddening itch that is the feature of allergic conjunctivitis.
Beyond its labeled indications, Acular is frequently used off label by ophthalmologists and other eye care professionals for many inflammatory conditions of the anterior segment of the eye. These include the prophylaxis and treatment of cystoid macular edema following cataract surgery, the management of postoperative inflammation after various intraocular procedures, the treatment of episcleritis and anterior uveitis, and the prevention of miosis during cataract surgery. The versatility of ketorolac in ocular therapeutics reflects central role of prostaglandins in a broad spectrum of ocular inflammatory conditions.
Acular is also used for the management of chronic ocular surface inflammation associated with conditions such as dry eye disease, blepharitis, and contact lens related irritation. While the primary therapy for these conditions involves lubrication, lid hygiene, and avoidance of triggers, the addition of topical NSAID therapy can help break the cycle of inflammation that perpetuates and exacerbates the underlying condition.
Dosage forms and strengths available
Acular is supplied as a sterile ophthalmic solution in a strength of zero point five percent ketorolac tromethamine, which corresponds to five milligrams of ketorolac per milliliter of solution. The medication is packaged in convenient dropper bottles that allow for precise dosing and easy self administration. The solution is clear, colorless to slightly yellow, and should be free of visible particulate matter. Any change in the appearance of the solution, including cloudiness, discoloration, or the appearance of particles, may indicate contamination or degradation, and the bottle should be discarded.
The recommended dosing regimen for Acular varies depending on the indication for which it is being used. For the relief of ocular pain and burning following corneal refractive surgery, the recommended dosage is one drop instilled into the affected eye or eyes four times daily as needed for pain, for up to four days following the procedure. This short term, as needed dosing regimen balances adequate analgesia with the avoidance of unnecessary exposure to the medication and its potential adverse effects on the corneal surface.
For the treatment of ocular itching associated with seasonal allergic conjunctivitis, the recommended dosage is one drop instilled into the affected eye or eyes four times daily for as long as the patient is exposed to the offending allergen and experiencing symptoms. The duration of therapy for allergic conjunctivitis is typically limited to the allergy season, although patients with perennial allergies may require longer term treatment. The lowest effective dose and frequency should be used to minimize the risk of corneal adverse effects.
When Acular is used for off label indications, the dosing regimen is determined by the prescribing ophthalmologist based on the condition being treated, the severity of inflammation, and the individual patient’s response to therapy. Typical regimens range from one drop twice daily to one drop four times daily, and the duration of treatment varies from a few days for acute postoperative inflammation to several weeks or months for chronic inflammatory conditions.
Proper administration technique
Correct administration of Acular is essential for ensuring that the medication reaches the ocular surface in sufficient concentration to exert its therapeutic effect while minimizing contamination of the bottle and the risk of systemic absorption. Patients should be instructed on the proper technique for instilling eye drops, and the importance of adherence to these instructions should be emphasized.
Before administering Acular, the patient should wash their hands thoroughly with soap and water and dry them with a clean towel. The bottle should be inspected visually to ensure that the solution is clear and free of particles, and the expiration date should be verified. The bottle should be shaken gently if indicated in the product labeling, although shaking is generally not required for Acular solution.
To administer the drop, the patient should tilt their head backward and look upward. The lower eyelid should be gently pulled down with the index finger of the nondominant hand to create a small pocket or cul de sac between the eyelid and the eye. The dropper tip should be held close to the eye but should not touch the eye, the eyelid, or any other surface, as this could introduce bacteria or other contaminants into the bottle. One drop should be gently squeezed into the conjunctival sac.
After instilling the drop, the patient should gently close the eye without squeezing the eyelids tightly together. Squeezing can force the medication out of the eye through the tear ducts. The patient should apply gentle pressure to the inner corner of the eye at the bridge of the nose for approximately one to two minutes. This technique, known as nasolacrimal occlusion, prevents the medication from draining away through the nasolacrimal duct into the nasal cavity and systemic circulation, maximizing the local ocular effect and minimizing systemic exposure.
If more than one topical ophthalmic medication is being used, the different products should be administered at least five minutes apart to prevent the second drop from washing out the first. The recommended order of administration is generally to start with solutions, which have the lowest viscosity, and progress to suspensions and then ointments, which are thicker and may interfere with the absorption of subsequently administered medications. Contact lenses should be removed before instilling Acular and should not be reinserted for at least fifteen minutes after administration.
Mechanism of action at the molecular level
The therapeutic activity of Acular is mediated through its inhibition of prostaglandin synthesis in the anterior segment of the eye. Ketorolac tromethamine is a nonselective inhibitor of both COX-1 and COX-2, the two isoforms of the cyclooxygenase enzyme that catalyze the committed step in prostaglandin biosynthesis. By inhibiting both isoforms, ketorolac blocks the production of the full spectrum of prostaglandins that contribute to ocular inflammation and pain.
Prostaglandin synthesis begins with the release of arachidonic acid from membrane phospholipids by the enzyme phospholipase A2, a reaction that is stimulated by tissue injury, inflammation, and various cellular signals. Once released, arachidonic acid is a substrate for COX-1 and COX-2, which catalyze its conversion to prostaglandin H2, the common precursor of all prostaglandins. Tissue specific isomerases then convert prostaglandin H2 into the various prostaglandin species, including prostaglandin E2 and prostaglandin F2 alpha, that are the primary mediators of ocular inflammation.
In the eye, prostaglandin E2 is a potent mediator of inflammation, causing vasodilation of conjunctival and episcleral blood vessels, increasing vascular permeability and leading to edema and cellular infiltration, lowering intraocular pressure through increased uveoscleral outflow, and causing miosis or pupillary constriction. Prostaglandin F2 alpha also contributes to inflammation and is a particularly important mediator of the pain that follows corneal surgery and of the itching that characterizes allergic conjunctivitis.
By inhibiting COX-1 and COX-2, ketorolac effectively shuts down the production of these proinflammatory prostaglandins at the site of ocular inflammation. The reduction in prostaglandin levels leads to decreased vasodilation and redness, reduced vascular permeability and edema, less stimulation of pain nerve endings, and attenuation of the itch response. Because ketorolac acts at the level of prostaglandin synthesis rather than at specific prostaglandin receptors, it blocks the effects of all prostaglandin species, providing broad spectrum anti inflammatory activity.
Ketorolac also has analgesic properties that are independent of its anti inflammatory effects. In the cornea, the site of some of the most intense ocular pain, prostaglandins sensitize the nociceptive nerve endings to mechanical and chemical stimuli, lowering the threshold for pain perception. By reducing prostaglandin levels, ketorolac raises the threshold and reduces the intensity of pain signals generated by the injured or inflamed cornea. Also, ketorolac may have direct effects on pain signaling pathways that contribute to its analgesic efficacy.
Clinical trial data and evidence of efficacy
The efficacy of Acular for its labeled indications has been shown in well controlled clinical trials. For the management of pain following corneal refractive surgery, Acular was compared to placebo in randomized, double masked studies in patients undergoing radial keratotomy and photorefractive keratectomy. Patients treated with Acular reported less pain, burning, and stinging compared to those receiving placebo, and the analgesic effect was evident within the first few hours after surgery.
The efficacy of Acular for the treatment of allergic conjunctivitis was established in studies that used the conjunctival allergen challenge model, a standardized method for evaluating antiallergic medications. In this model, patients with known allergic sensitivities are exposed to controlled doses of allergen, and their ocular symptoms are assessed. Acular reduced ocular itching, the primary endpoint, compared to placebo, and the effect was evident within minutes of allergen exposure and persisted for several hours.
Beyond the labeled indications, a large body of clinical literature supports the use of ketorolac for the prophylaxis and treatment of cystoid macular edema after cataract surgery. Cystoid macular edema, a swelling of the central retina that can cause blurred and distorted vision, is a complication that occurs in a significant minority of patients following cataract extraction and intraocular lens implantation. Prostaglandins released during surgery are believed to disrupt the blood retinal barrier, allowing fluid to accumulate in the macula, and ketorolac’s ability to suppress prostaglandin synthesis makes it a logical therapy for preventing and treating this condition.
Multiple studies have demonstrated that the use of topical ketorolac, either alone or in combination with topical corticosteroids, reduces the incidence and severity of angiographic cystoid macular edema after cataract surgery. Some studies have also shown that ketorolac improves visual outcomes and reduces the need for rescue therapy with more potent anti inflammatory agents. The combination of ketorolac and a corticosteroid may provide additive or synergistic effects, as the two classes of drugs inhibit the inflammatory cascade at different points.
Acular has also been studied for the prevention of miosis during cataract surgery, where a small pupil can complicate the operative procedure. Prostaglandins released during surgical manipulation of the iris can cause intraoperative miosis, and pretreatment with ketorolac has been shown to reduce this effect, allowing the surgeon to maintain a more stable and adequately sized pupil throughout the procedure.
Safety profile and common side effects
Acular is generally well tolerated when used as directed, with most adverse effects being mild, transient, and limited to the ocular surface. The most commonly reported adverse effects in clinical trials included transient ocular stinging and burning upon instillation of the drops, which typically resolves within seconds to minutes. This stinging sensation is common to many ophthalmic solutions and is not indicative of any damage to the ocular tissues.
Ocular irritation, including a foreign body sensation, conjunctival hyperemia or redness, and superficial punctate keratitis, which appears as tiny irregularities on the corneal surface visible under the slit lamp, have been reported with the use of Acular. These effects are generally mild and reversible upon discontinuation of the medication. The incidence of corneal adverse effects increases with higher doses and longer durations of treatment, and patients should be monitored accordingly when using Acular for extended periods.
Allergic reactions to ketorolac are uncommon but have been reported and may manifest as conjunctival injection, chemosis or swelling of the conjunctiva, eyelid edema, and itching. Patients with a known hypersensitivity to aspirin or other nonsteroidal anti inflammatory drugs should use Acular with caution, as cross reactivity can occur. Severe allergic reactions, including anaphylaxis, are rare with topical ophthalmic NSAIDs but have been reported with systemic administration of ketorolac.
Corneal complications have been reported with the use of topical ophthalmic NSAIDs as a class, including corneal melting, perforation, and ulceration, particularly in patients with compromised corneal epithelium or with preexisting corneal disease such as rheumatoid arthritis, dry eye syndrome, or ocular surface disorders. These complications are more likely to occur with prolonged use, with the use of multiple NSAID containing drops, and in patients with risk factors for impaired corneal wound healing. The use of Acular for more than the recommended duration should be avoided, and patients should be instructed to report any new or worsening eye symptoms promptly.
Systemic absorption of ketorolac following topical ophthalmic administration is minimal, and systemic side effects are uncommon. However, patients who are particularly sensitive to the effects of NSAIDs, including those with a history of peptic ulcer disease, gastrointestinal bleeding, renal impairment, or bleeding disorders, should be aware that even the small amounts of ketorolac absorbed systemically could potentially exacerbate these conditions. The nasolacrimal occlusion technique described earlier can help minimize systemic absorption.
Delayed wound healing is a theoretical concern with topical NSAIDs, including Acular, as prostaglandins affect the normal healing process. In the cornea, prostaglandins may promote epithelial cell migration and proliferation, and their inhibition could potentially slow the reepithelialization of corneal wounds. Clinical studies have not consistently demonstrated a clinically significant delay in healing with standard postoperative NSAID regimens, but caution is warranted, particularly in patients with preexisting corneal disease or those undergoing procedures that involve extensive corneal epithelial debridement.
Contraindications and precautionary measures
Acular is contraindicated in patients with a known hypersensitivity to ketorolac or to any component of the formulation. This includes patients who have experienced allergic reactions to ketorolac, whether administered topically to the eye, orally, or by injection. Patients with a history of asthma, urticaria, or other allergic type reactions following the use of aspirin or other NSAIDs should also avoid using Acular, as the risk of a similar reaction, including potentially severe bronchospasm, is elevated in these individuals.
Patients with active or suspected corneal infection, including bacterial, viral, fungal, or protozoal keratitis, should not use Acular without concurrent appropriate anti infective therapy. The anti inflammatory effects of NSAIDs can mask the signs of worsening infection, and the impairment of the normal inflammatory response may interfere with the body’s ability to clear the infection. The decision to use Acular in the presence of an ocular infection should be made by an ophthalmologist who can weigh the risks and benefits of treatment.
Patients who are scheduled for or who have recently undergone ocular surgery other than corneal refractive procedures should discuss the use of Acular with their ophthalmologist. While ketorolac is frequently used after cataract surgery for the prevention of cystoid macular edema, the specific timing, dosing, and duration of treatment should be determined by the surgeon based on the individual patient’s risk factors and the specific characteristics of the surgical procedure.
Patients with preexisting corneal disease, including corneal epithelial defects, neurotrophic keratopathy, dry eye syndrome, and other conditions that compromise the integrity of the corneal surface, should use Acular with caution, as the risk of corneal melting, ulceration, and perforation with topical NSAIDs may be increased in these patients. The benefits of NSAID therapy should be weighed carefully against the potential risks, and patients should be monitored closely for signs of corneal toxicity.
The safety of Acular during pregnancy has not been established, and the medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Systemically administered NSAIDs, including ketorolac, can cause premature closure of the ductus arteriosus and other adverse fetal effects when used during the third trimester. While the systemic absorption of ketorolac from ophthalmic administration is very low, the medication should be avoided during late pregnancy if possible, and its use at any stage of pregnancy should be discussed with the healthcare provider.
Nursing mothers should exercise caution when using Acular, as it is not known whether ketorolac is excreted into human breast milk following ophthalmic administration. The systemic levels achieved after topical ocular administration are very low, and the risk to a nursing infant is likely minimal, but the decision to use Acular while breastfeeding should involve a discussion of the potential risks and benefits.
Drug interactions of note
The potential for systemic drug interactions with Acular is low due to the minimal systemic absorption of ketorolac following topical ophthalmic administration. However, caution is advised when Acular is used in patients who are taking other NSAIDs, whether systemically or topically, as the additive effects on cyclooxygenase inhibition could theoretically increase the risk of NSAID related adverse effects, including gastrointestinal ulceration and bleeding, renal impairment, and impaired platelet function.
The concomitant use of Acular with topical ophthalmic corticosteroids is common for postoperative inflammation and may provide additive or synergistic anti inflammatory effects. The combination does not appear to increase the risk of ocular adverse effects beyond that expected with either agent alone, and it is a well established practice in ophthalmology. However, the use of multiple topical medications increases the complexity of the postoperative regimen and the potential for dosing errors, and clear instructions should be provided to the patient.
Patients who are taking anticoagulant or antiplatelet medications, including warfarin, clopidogrel, aspirin, or newer direct oral anticoagulants, should be aware that all NSAIDs, including ketorolac, can inhibit platelet aggregation and prolong bleeding time. While the systemic absorption of ketorolac from ophthalmic administration is minimal, the potential for an additive effect on hemostasis exists, and patients should report any unusual bruising or bleeding to their healthcare provider.
The use of Acular with other topical ophthalmic medications, including antibiotics, corticosteroids, cycloplegics, and pressure lowering agents, is generally safe and well tolerated. The different drops should be administered at least five minutes apart to prevent washout and interference with drug absorption, and the recommended order of administration should be followed. If the patient has any questions about the compatibility of their various eye drops, they should consult their pharmacist or healthcare provider.
Contact lens wearers should be advised that the preservative in Acular, benzalkonium chloride, can accumulate in soft contact lenses and cause ocular irritation. Contact lenses should be removed before instilling Acular and should not be reinserted for at least fifteen minutes after administration. Patients who wear contact lenses on a daily basis should consider the timing of Acular administration relative to their lens wear schedule to minimize disruption and to protect the lenses from discoloration and damage.
Comparisons with other ocular anti inflammatory agents
Acular has a specific niche within the therapeutic options of ocular anti inflammatory medications, and its position relative to other available agents is defined by its unique combination of efficacy, safety, and convenience. Compared to topical corticosteroids, the other major class of ocular anti inflammatory drugs, Acular offers a different risk profile that may be advantageous in certain clinical situations.
Corticosteroids, such as prednisolone acetate, dexamethasone, loteprednol, and fluorometholone, are more potent anti inflammatory agents than NSAIDs and are the foundation of treatment for severe ocular inflammation, including that associated with uveitis, severe allergic reactions, and major intraocular surgery. However, corticosteroids carry significant risks, including elevation of intraocular pressure, acceleration of cataract formation, increased susceptibility to ocular infections, and delayed wound healing. For conditions in which NSAIDs provide sufficient anti inflammatory activity, the avoidance of these corticosteroid related risks is a meaningful advantage.
Compared to other topical ophthalmic NSAIDs, including diclofenac, bromfenac, flurbiprofen, and nepafenac, Acular offers a well established efficacy and safety profile supported by decades of clinical experience. Ketorolac was one of the first ophthalmic NSAIDs to be approved by regulatory agencies, and its effects in many ocular inflammatory conditions have been documented in the peer reviewed literature. The choice among the various ophthalmic NSAIDs is often based on physician familiarity, patient tolerance, cost considerations, and insurance formularies.
For the treatment of allergic conjunctivitis, Acular competes with many antiallergy eye drops, including antihistamines such as olopatadine and ketotifen, mast cell stabilizers such as cromolyn and lodoxamide, and combination antihistamine and mast cell stabilizer products. These antiallergy agents act earlier in the allergic cascade, preventing the degranulation of mast cells and blocking the effects of preformed histamine, whereas NSAIDs act downstream by inhibiting prostaglandin synthesis. The choice among these agents depends on the specific symptoms that are most bothersome to the patient and the individual’s response to each class of medication.
Patient education and counseling essentials
Effective patient education is critical for achieving optimal outcomes with Acular, whether the medication is being used for postoperative pain relief, allergic conjunctivitis, or off label indications. Patients should be educated about the purpose of the medication, the correct technique for instilling the drops, the expected benefits and timeline of treatment, and the potential adverse effects that require medical attention.
The proper technique for eye drop instillation should be demonstrated and reviewed with the patient at the time of prescribing and at follow up visits as needed. Common errors, including touching the dropper tip to the eye or eyelid, missing the eye entirely, and blinking or squeezing the eyelids forcefully after instillation, should be specifically addressed. The rationale for nasolacrimal occlusion, to maximize local effect and minimize systemic absorption, should be explained.
Patients should be informed that transient stinging or burning upon instillation of Acular is common and expected, and that this sensation typically resolves within seconds. If the stinging is severe, persistent, or worsening with continued use, the patient should consult their healthcare provider, as these could be signs of hypersensitivity or other adverse reaction. The use of refrigerated drops, if permitted by the product labeling and if tolerable to the patient, may reduce the stinging sensation.
The importance of adherence to the prescribed dosing regimen should be emphasized, as inadequate dosing may fail to control inflammation adequately while excessive dosing may increase the risk of corneal and other adverse effects. The recommended duration of treatment should be respected, and patients should be advised not to continue using Acular beyond the prescribed period without consulting their healthcare provider, even if they have medication remaining in the bottle.
Patients should be counseled about the signs and symptoms of serious adverse effects that require prompt medical attention, including worsening eye pain, worsening redness, purulent discharge, decreasing vision, increased sensitivity to light, or the appearance of a white spot on the cornea that could indicate corneal ulceration or melting. Early recognition and appropriate management of these complications can prevent permanent vision impairment.
The importance of hand hygiene before and after instilling eye drops should be emphasized to prevent contamination of the bottle and to reduce the risk of introducing infection into the eye. Patients should be instructed to avoid allowing the dropper tip to touch any surface, including the eye, eyelids, fingers, or countertop, and to replace the cap tightly after each use. If the dropper tip does become contaminated, the bottle should be discarded to avoid the risk of microbial contamination of the solution.
Storage and handling requirements
Proper storage of Acular is important for maintaining the sterility and stability of the solution. The product should be stored at controlled room temperature, protected from light and excessive heat, and kept in its original container. The bottle should be stored upright to prevent leakage, and the cap should be securely closed after each use to prevent contamination and evaporation of the vehicle.
The preservative in Acular, typically benzalkonium chloride, provides protection against microbial contamination during repeated use of the multi dose bottle. However, the preservative is not indefinitely effective, and contamination can occur if the dropper tip is touched or if the bottle is stored under conditions that promote microbial growth. The medication should be used within the recommended in use period after opening, which is typically four weeks, and any unused product should be discarded after this period.
Patients should be encouraged to write the date on which the bottle was opened on the label or carton to help track the in use period. This simple practice can prevent the accidental use of expired or potentially contaminated medication that could compromise the safety and efficacy of treatment. If the solution changes color, becomes cloudy, or develops visible particles, it should be discarded immediately.
Acular should be kept out of the reach of children to prevent accidental ingestion, which could cause systemic NSAID toxicity. While the volume of medication in an eye drop bottle is small, even one bottle could contain enough ketorolac to cause significant toxicity in a young child. In case of accidental ingestion, emergency medical attention should be sought, and the poison control center should be contacted for guidance on appropriate management.
Obtaining acular through happy family pharmacy
Happy Family Pharmacy is proud to offer Acular over the counter, providing patients with direct and convenient access to this effective ophthalmic NSAID. Eye pain, itching, and inflammation are common problems that can impair quality of life, and timely access to effective treatment is essential for relieving symptoms and preventing the complications of untreated ocular inflammation.
Our Acular products are authentic, properly manufactured, and carefully handled to ensure that every bottle delivers the expected therapeutic benefit. We source our medications from licensed pharmaceutical manufacturers and distributors, and we adhere to rigorous quality control standards throughout our supply chain. When you order Acular from Happy Family Pharmacy, you can be confident that you are receiving a genuine, high quality ophthalmic solution that meets all applicable standards for purity, potency, and sterility.
At Happy Family Pharmacy, we are committed to supporting the eye health of our customers through reliable access to quality ophthalmic medications, competitive pricing, and exceptional customer service. We understand that eye problems demand prompt attention, and our efficient ordering and shipping processes are designed to ensure that your medication reaches you as quickly as possible.
Buy Acular Over The Counter at Happy Family Pharmacy
While Acular is available over the counter through our pharmacy, we encourage all of our customers to consult with an eye care professional if they have questions about the cause of their eye symptoms, the appropriate use of the medication, or the monitoring of their eye health during treatment. Some eye conditions that cause pain, redness, or itching can be serious and may require specific treatments beyond symptomatic relief with Acular. Regular eye examinations are important for maintaining ocular health and detecting conditions that could threaten vision.
We invite you to explore the Happy Family Pharmacy website to learn more about Acular and our other ophthalmic products, to place your order conveniently online, and to experience the quality and service that have made us a trusted name in over the counter pharmaceuticals. Your eye comfort and vision are precious, and Happy Family Pharmacy is dedicated to helping you protect and preserve them with the medications and support that you deserve.
With Acular available over the counter from Happy Family Pharmacy, relief from ocular itching, pain, and inflammation is more accessible and more affordable than ever before. Whether you are recovering from eye surgery, battling seasonal allergies, or dealing with chronic ocular surface inflammation, Acular provides the targeted anti inflammatory action you need. Trust Happy Family Pharmacy to be your partner in eye health and your source for the quality ophthalmic medications that help you see and feel your best every day.